We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Read more
Bachem may be closer to a step-up in growth than most people expect as new manufacturing sites ramp faster and production gets more automated. The upside comes with real pressure points though, including big expansion spending, a narrow product focus, and the risk that rivals catch up or global supply chains get disrupted.Read more
Tighter drug rules, pressure to keep healthcare costs down, and cheaper rivals could make it harder for Bachem to grow and keep charging premium prices. With big new factories coming online, the bigger question is whether demand stays strong enough to avoid excess capacity and squeezed profits.Read more
Key Takeaways Significant expansion in large-scale manufacturing and process automation positions Bachem for outsized growth and improved margins amid rising demand for peptide and oligonucleotide drugs. Strong long-term customer partnerships and leadership in advanced therapeutics offer recurring, less volatile revenue and structural advantage as biopharma outsourcing intensifies.Read more
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
